High Blood Pressure & Cardiovascular Prevention最新文献

{"title":"Sex Differences in Ambulatory Central Blood Pressure and Arterial Stiffness in Hemodialysis Patients.","authors":"Artemios G Karagiannidis, Marieta P Theodorakopoulou, Fotini Iatridi, Antonios Karpetas, Areti Georgiou, Sofia Manti, Panagiota Anyfanti, Eleni Gavriilaki, George Giannakoulas, Pantelis Sarafidis","doi":"10.1007/s40292-025-00713-0","DOIUrl":"https://doi.org/10.1007/s40292-025-00713-0","url":null,"abstract":"<p><strong>Introduction: </strong>Sex differences have a significant role on epidemiology of cardiovascular complications in chronic kidney disease. Among hemodialysis patients, central blood pressure (BP) levels and increased arterial stiffness parameters are independent predictors of cardiovascular and all-cause- mortality.</p><p><strong>Aim: </strong>To examine the potential differences in ambulatory central BP and arterial stiffness parameters between male and female hemodialysis patients.</p><p><strong>Methods: </strong>A total of 129 male and 91 female hemodialysis patients were included in this analysis. All participants underwent 48-h ambulatory BP monitoring with Mobil-O-Graph-NG; indices of central hemodynamics (SBP, DBP and pulse pressure), wave reflection (augmentation pressure (AP) and augmentation index (AIx)) and pulse wave velocity (PWV) were estimated.</p><p><strong>Results: </strong>Age, dialysis vintage and history of major comorbidities did not differ between men and women. Male patients had higher 48-h cSBP (124.7±15.7 vs. 119.8±16.7 mmHg, p=0.027) and 48-h DBP (83.7±12.2 vs. 77.5±11.9 mmHg, p<0.001) compared to female patients; relevant differences were also evident during the 44-h (excluding hemodialysis), 1st 24-h and 2nd 24-h periods and the corresponding daytime and nighttime periods of the recording. Central pulse pressure did not differ between groups. Regarding wave reflection parameters, AP, AIx, and AIx(75) were significantly lower in males versus females during the 48-h (AIx, 25.6±8.2 vs. 32.3±8.6 mmHg, p<0.001), 44-h, 1st and 2nd 24-h and also during respective daytime and nighttime periods. The two groups displayed similar PWV during all studied intervals (48-h PWV, 9.6±1.9 vs 9.7±2.1 m/s, p=0.612).</p><p><strong>Conclusions: </strong>Male hemodialysis patients present with higher levels of ambulatory central BP but significantly lower levels of AP, AIx and AIx(75) than females. PWV does not differ between sexes.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors' Response to Comment by Mohammad Jameel Rahmatullah Suhotoo on \"Epistaxis and Clinic Blood Pressure Values: Is There a Relationship?\"","authors":"Claudia Lodovica Modesti, Gabriele Testa, Massimo Salvetti, Davide Lombardi, Cesare Piazza, Maria Lorenza Muiesan","doi":"10.1007/s40292-025-00711-2","DOIUrl":"https://doi.org/10.1007/s40292-025-00711-2","url":null,"abstract":"","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Reply: \"Epistaxis and Clinic Blood Pressure Values: Is There a Relationship?\"","authors":"Mohammad Jameel Rahmatullah Suhotoo","doi":"10.1007/s40292-025-00712-1","DOIUrl":"https://doi.org/10.1007/s40292-025-00712-1","url":null,"abstract":"","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-participation Cardiovascular Evaluation for Paris 2024 Olympic Games in Elite Athletes: The Italian Experience.","authors":"Maria Rosaria Squeo, Armando Ferrera, Giuseppe Di Gioia, Federica Mango, Viviana Maestrini, Sara Monosilio, Erika Lemme, Simone Crotta, Alessandro Spinelli, Andrea Serdoz, Roberto Fiore, Domenico Zampaglione, Cosimo Damiano Daniello, Massimo Volpe, Marco Bernardi, Antonio Pelliccia, Largo Piero Gabrielli","doi":"10.1007/s40292-025-00709-w","DOIUrl":"https://doi.org/10.1007/s40292-025-00709-w","url":null,"abstract":"<p><strong>Introduction: </strong>Olympic athletes represent a special subset of the athletic population and deserve a specialized medical approach. In view of the 2024 Paris Olympic Games, we developed and implemented a comprehensive medical protocol including (other than the standard screening with ECG, physical and history) cardiopulmonary exercise test, echocardiography and full blood and urine tests.</p><p><strong>Aim: </strong>Our aim was to assess the prevalence and type of cardiovascular abnormalities in athletes candidate to Paris 2024 Olympic Games, after implementation of this Olympic medical program.</p><p><strong>Methods: </strong>We enrolled 772 elite athletes, who underwent a comprehensive, multidisciplinary evaluation, including full panel of blood and urine tests, electrocardiography, trans-thoracic echocardiography (TTE) and a cardiopulmonary exercise test (CPET).</p><p><strong>Results: </strong>Of the 772 elite athletes, 363 (47%) were female. A substantial subset of 145 athletes (18.8%) showed one or more abnormalities. Specifically, either abnormal basal ECG findings (n = 26, 17.9%), abnormal TTE results (n = 45, 31%), high blood pressure (n = 2, 1.4%) or exercise induced arrhythmias (n = 49, 33.8%) were detected. 10 athletes (6.9%) showed both abnormal ECGs and exercise induced arrhythmias, and 13 athletes (9%) showed both ECG and echocardiographic abnormal findings. After further and more detailed investigations, of the 145 athletes showing cardiovascular abnormalities at the initial screening, in 4 of them were cardiac conditions implying potential risk of sudden cardiac death were identified and therefore they were withdrawn from competitive sport. Full blood test analysis identified metabolic abnormalities in 200 subjects. Of these, 165 (21%) showed hypercholesterolemia.</p><p><strong>Conclusions: </strong>Olympic athletes, despite the highest level of physical performance, are not exempt from cardiovascular and metabolic diseases, including a small proportion of cardiac conditions at risk of SCD. More advanced diagnostic tools, including CPET, echocardiography and full blood tests, implemented in our protocol, were required to identify hidden cardiovascular abnormalities that could have jeopardized athlete's health and performance.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aortic Remodeling in Patients with Arterial Hypertension: Pathophysiological Mechanisms, Therapeutic Interventions and Preventive Strategies-A Position Paper from the Heart and Hypertension Working Group of the Italian Society of Hypertension.","authors":"Costantino Mancusi, Christian Basile, Ilaria Fucile, Carlo Palombo, Maria Lembo, Giacomo Buso, Claudia Agabiti-Rosei, Valeria Visco, Antonietta Gigante, Giuliano Tocci, Alessandro Maloberti, Chiara Tognola, Giacomo Pucci, Rosa Curcio, Sebastiano Cicco, Federica Piani, Marialuisa Sveva Marozzi, Alberto Milan, Dario Leone, Chiara Cogliati, Riccardo Schiavon, Massimo Salvetti, Michele Ciccarelli, Nicola De Luca, Massimo Volpe, Maria Lorenza Muiesan","doi":"10.1007/s40292-025-00710-3","DOIUrl":"https://doi.org/10.1007/s40292-025-00710-3","url":null,"abstract":"<p><p>In patient with arterial hypertension the whole aorta is exposed to increased wall stress due to pressure overload. Different blood pressure (BP) components have been reported as main determinant of aortic remodelling. In particular increased diastolic BP has been associated with aortic dilatation across all its segments with smaller increase in aortic root and ascending aorta related to increased systolic BP and pulse pressure. Optimal BP control is crucial to prevent development of aortic aneurysm and acute aortic disease. Many studies have evaluated the role of different antihypertensive drug classes for prevention of adverse aortic remodelling including beneficial effects of ACEIs, ARBs, dihydropyridinic calcium channel blockers and Beta-blockers. The present review discusses pathophysiological mechanisms, therapeutic interventions and preventive strategies for development of aortic remodeling in patients with arterial hypertension.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes in patients with cardiorenal multimorbidity: the role of serum uric acid/serum creatinine ratio.","authors":"Antonietta Gigante, Eleonora Assanto, Claudia Brigato, Chiara Pellicano, Francesco Iannazzo, Edoardo Rosato, Maurizio Muscaritoli, Claudio Ferri, Rosario Cianci","doi":"10.1007/s40292-025-00706-z","DOIUrl":"10.1007/s40292-025-00706-z","url":null,"abstract":"<p><strong>Introduction: </strong>Serum uric acid (SUA), the final product of purine metabolism, is an independent risk factor for cardiovascular (CV) disease. Since SUA levels depend on renal function, SUA to serum creatinine ratio (SUA/sCr) is emerging as a more specific biomarker of CV risk.</p><p><strong>Aim: </strong>To evaluate in hospitalized patients with cardiorenal multimorbidity (CRM) if the SUA/sCr ≥ 5.35 is associated with clinical outcomes. The primary outcome was in-hospital mortality. The secondary outcome was the composite of all-cause of mortality and adverse clinical events.</p><p><strong>Methods: </strong>We conducted a retrospective review of medical records from consecutive CRM inpatients admitted to the medical ward. The composite endpoint was calculated as all-cause mortality and adverse clinical events such as acute coronary syndrome, stroke, infections, and renal replacement therapy.</p><p><strong>Results: </strong>In our cohort, 141 patients (mean age of 75.6 ± 10.2 years) were identified with CRM. In-hospital mortality occurred in 17 patients (16%), and 64 patients (60.4%) experienced adverse clinical outcomes. Among the 106 patients, 20 (18.9%) had an SUA/sCr ≥ 5.35, while 86 (81.1%) had an SUA/sCr < 5.35. Male gender was significantly associated with SUA/sCr ≥ 5.35 (p = 0.007). In-hospital mortality was significantly higher in patients with SUA/sCr ≥ 5.35 (p = 0.010), and a positive correlation with adverse clinical outcomes was documented in this subgroup (p = 0.012).</p><p><strong>Conclusion: </strong>in patients with CRM, SUA/sCr ≥ 5.35 is associated with increased in-hospital mortality and worse clinical outcomes. The ratio and related cut-off value of SUA/sCr could represent a useful biomarker to assess in-hospital complications in CRM patients.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"209-216"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143541093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Posterior Reversible Leukoencephalopathy Syndrome During Hypertensive Crisis in Obstructive Sleep Apnea Syndrome: Searching for a Link.","authors":"Gioia Torin, Laura Schiavon, Marta Milan, Silvia Rizzati, Carla Destro, Stefano Cuppini, Alberto Mazza","doi":"10.1007/s40292-025-00702-3","DOIUrl":"10.1007/s40292-025-00702-3","url":null,"abstract":"<p><p>Posterior reversible encephalopathy syndrome (PRES) may present with different clinical symptoms including visual disturbance, headache, seizures and impaired consciousness. Brain MRI shows oedema, usually involving the posterior subcortical regions. Triggering factors include hypertension and obstructive sleep apnea syndrome. The mechanism underlying PRES is under debate, but endothelial dysfunction is implicated. Treatment goals of PRES are gradual blood pressure (BP) lowering to avoid sudden hypoperfusion of vital organs and prevention and management of seizures. PRES usually has a favorable prognosis, but delayed diagnosis and treatment may lead to cardiovascular morbidity, mortality or irreversible neurological deficits.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"223-225"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143003764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2024 consensus document of the Italian Society of Arterial Hypertension (SIIA) and the Italian Society of Cardiovascular Prevention (SIPREC): update on LDL cholesterol lowering in patients with arterial hypertension.","authors":"Maria Lorenza Muiesan, Agostino Virdis, Giuliano Tocci, Claudio Borghi, Arrigo F G Cicero, Claudio Ferri, Matteo Pirro, Alberto Corsini, Massimo Volpe","doi":"10.1007/s40292-024-00700-x","DOIUrl":"10.1007/s40292-024-00700-x","url":null,"abstract":"<p><p>Hypertension and hypercholesterolemia often occur in the same individuals, increasing the risk of major cardiovascular (CV) outcomes, including myocardial infarction, stroke, CV death, as well as other CV complications. Concomitant management of these condition now represent a crucial step to reduce individual global CV risk and improve CV disease prevention in daily clinical practice. Given the high prevalence of hypertension and hypercholesterolemia in general population and their impact on health status, several pharmacological options are currently available to achieve the recommended therapeutic targets. These drugs, mostly including statins, ezetimibe, bempedoic acid, proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors and inclisiran, can be used either in monotherapies or in combination therapies, with different clinical indications, therapeutic efficacy and tolerability profile. Decision among different drug classes and dosages, as well as choice between monotherapy or combination therapy (fixed or free), largely depend on individual global CV risk profile and therapeutic targets of low-density lipoprotein (LDL) cholesterol levels to be achieved under pharmacological therapy. The present consensus document represents an update of the previous document published on 2022 and endorsed by the Italian Society of Hypertension (SIIA) and the Italian Society of Cardiovascular Prevention (SIPREC). Here we propose a novel paradigm for the treatment of the patients with hypertension and hypercholesterolemia at high or very high cardiovascular risk. In addition, the pharmacological properties, and the clinical efficacy of novel agents recently approved for a tailored therapy of hypercholesterolemia in patients with atherosclerotic CV disease, including PCSK9 inhibitors and bempedoic acid, will be summarized.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"151-163"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Uric Acid/Serum Creatinine Ratio and Chronic Vascular Lesions on Renal Biopsy: A Retrospective Observational Study.","authors":"Antonietta Gigante, Chiara Pellicano, Carmen Gallicchio, Michele Melena, Melania Fiorino, Edoardo Rosato, Konstantinos Giannakakis, Andrea Ascione, Maurizio Muscaritoli, Rosario Cianci","doi":"10.1007/s40292-024-00699-1","DOIUrl":"10.1007/s40292-024-00699-1","url":null,"abstract":"<p><strong>Introduction: </strong>Increased serum uric acid (SUA) levels are found in cardiovascular and kidney diseases, associated with the development of vascular injury. Uric acid stimulates the inflammatory pathways, promotes vascular smooth muscle cells proliferation, activates renin-angiotensin system leading to the development and progression of vascular damage. Renal function-normalized uric acid [SUA to serum creatinine ratio (SUA/SCr)] has been suggested to be a better indicator of uric acid.</p><p><strong>Aim: </strong>To investigate the correlation between SUA level and SUA/SCr in the development of chronic and vascular lesions (CVL) in patients with primary glomerulonephritis (GN).</p><p><strong>Methods: </strong>A retrospective observational study was conducted in 95 consecutive renal native biopsies performed at Policlinico Umberto I of Rome (Italy). Patient inclusion criteria were age ≥ 18 years, a renal biopsy confirming diagnosis of primary GN, the availability of complete demographic, clinical, pathological, and laboratory data.</p><p><strong>Results: </strong>Median SCr was 1.06 mg/dl (IQR 0.77;1.70) with a median eGFR of 70.40 ml/min (IQR 40.40;105). Median SUA was 5.90 mg/dl (IQR 4.30;6.90) and median SUA/SCr was 4.70 (IQR 3.20;6.80). CVL were reported in 56 (58.9%) patients. Median SUA/SCr was significantly lower in patients with CVL than patients without CVL [3.95 (IQR 2.65;6) vs 5.90 (IQR 4.30;7.20), p<0.01]. Logistic regression analysis showed that SUA/SCr ≤ 4.05 [OR 5.451 (95% CI 1.222;24.325), p<0.05] was independently associated with CVL.</p><p><strong>Conclusions: </strong>CVL play a crucial role in the progression of kidney disease. SUA/SCr ≤ 4.05 is associated with CVL in patients with primitive GN.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"165-170"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Minimal-Advice\" on Salt Intake: Results of a Multicentre Pilot Randomised Controlled Trial on Hypertensive Patients.","authors":"Lanfranco D'Elia, Pasquale Strazzullo, Antonio Del Giudice, Giovambattista Desideri, Rosario Di Quattro, Claudio Ferri, Alessandra Grossi, Lorenzo Malatino, Francesca Mallamaci, Andrea Maresca, Michele Meschi, Alessia Casola, Pietro Nazzaro, Marco Pappaccogli, Franco Rabbia, Carla Sala, Ferruccio Galletti","doi":"10.1007/s40292-025-00704-1","DOIUrl":"10.1007/s40292-025-00704-1","url":null,"abstract":"<p><strong>Introduction: </strong>A strong and well-known association exists between salt consumption, potassium intake, and cardiovascular diseases. MINISAL-SIIA results showed high salt and low potassium consumption in Italian hypertensive patients. In addition, a recent Italian survey showed that the degree of knowledge and behaviour about salt was directly interrelated, suggesting a key role of the educational approach.</p><p><strong>Aim: </strong>The present multicentre randomised controlled trial study aimed to evaluate the efficacy of a short-time dietary educational intervention by a physician, only during the first visit, on sodium and potassium intake in hypertensive patients.</p><p><strong>Methods: </strong>Two-hundred-thirty hypertensive subjects participating in the MINISAL-SIIA study were enrolled for this study. After the randomisation, the participants were stratified into the educational intervention (EI) group (n = 109) and control group (C) (n = 121). Anthropometric indexes and blood pressure (BP) measurements were taken in the single-centre, and 24-hour urinary sodium (UrNa) and potassium (UrK) excretion were centrally measured.</p><p><strong>Results: </strong>After 3 months, there was a reduction in BP, UrNa, and body weight, and an increase in UrK in EI. By contrast, a lower decrease in BP was found in the C group, and a slight rise in UrNa and no substantial change in UrK were revealed. BP changes were positively and significantly associated with changes in UrNa only in EI.</p><p><strong>Conclusion: </strong>The main results of this trial indicate that a single brief educational intervention by a physician can lead to a reduction in salt intake and BP, and increased potassium consumption in hypertensive patients, without adverse effects.</p><p><strong>Trail registration: </strong>ClinicalTrial.gov registration number: NCT06651437.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"181-190"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}